Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVU120 and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
NCT06191263Phase 2Recruiting
- Sponsor
- Ryvu Therapeutics
- Start
- Jan 2024
- Primary completion
- Aug 2027
- Countries
- 4
01
Overview
A Phase 2 trial of rvu120 in acute myeloid leukemia (AML), sponsored by Ryvu Therapeutics. Started Jan 2024; status: recruiting.
02
Drugs
rvu120
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06191263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06191263.